Directing cancer cells to self-destruct with pro-apoptotic receptor agonists.
about
Digitoxin and a synthetic monosaccharide analog inhibit cell viability in lung cancer cellsHistone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIPTherapeutic antibodies, vaccines and antibodyomesYour neighbours matter - non-autonomous control of apoptosis in development and diseaseClinical perspectives of TRAIL: insights into central nervous system disordersEnhancing tumor-targeting monoclonal antibodies therapy by PARP inhibitorsTargeting the apoptosis pathway in hematologic malignanciesCaspase-8 expression is predictive of tumour response to death receptor 5 agonist antibody in Ewing's sarcomaOxidative stress, unfolded protein response, and apoptosis in developmental toxicityIntegrative analysis of kinase networks in TRAIL-induced apoptosis provides a source of potential targets for combination therapyRole of endoplasmic reticulum stress in alpha-TEA mediated TRAIL/DR5 death receptor dependent apoptosisGlycogen synthase kinase-3 inhibition sensitizes pancreatic cancer cells to TRAIL-induced apoptosisPreparation of a functional fluorescent human Fas ligand extracellular domain derivative using a three-dimensional structure guided site-specific fluorochrome conjugationAlcohol and thiamine deficiency trigger differential mitochondrial transition pore opening mediating cellular deathNovel HTS strategy identifies TRAIL-sensitizing compounds acting specifically through the caspase-8 apoptotic axis.Enhancement of TRAIL-induced apoptosis by 5-fluorouracil requires activating Bax and p53 pathways in TRAIL-resistant lung cancers.Protein kinase Cbeta modulates ligand-induced cell surface death receptor accumulation: a mechanistic basis for enzastaurin-death ligand synergy.2-Deoxy-D-glucose enhances TRAIL-induced apoptosis in human melanoma cells through XBP-1-mediated up-regulation of TRAIL-R2Voltage dependent anion channel-1 regulates death receptor mediated apoptosis by enabling cleavage of caspase-8.Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancerIdentification of novel molecular regulators of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in breast cancer cells by RNAi screening.Apoptotic death of cancer stem cells for cancer therapy.The Par-4-GRP78 TRAIL, more twists and turns.TRAIL receptor signaling regulation of chemosensitivity in vivo but not in vitroHDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells.Selective apoptotic cell death effects of oral cancer cells treated with destruxin BAnticancer activities of genistein-topotecan combination in prostate cancer cells.Histone deacetylase inhibitor sensitizes apoptosis-resistant melanomas to cytotoxic human T lymphocytes through regulation of TRAIL/DR5 pathway.Targeted knockdown of Bcl2 in tumor cells using a synthetic TRAIL 3'-UTR microRNAIdentification and characterization of a novel agonistic anti-DR4 human monoclonal antibody.High-content analysis of proapoptotic EphA4 dependence receptor functions using small-molecule libraries.Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled.Utilization of the cellular stress response to sensitize cancer cells to TRAIL-mediated apoptosis.Fenretinide-dependent upregulation of death receptors through ASK1 and p38α enhances death receptor ligand-induced cell death in Ewing's sarcoma family of tumours.Investigation of DNA damage response and apoptotic gene methylation pattern in sporadic breast tumors using high throughput quantitative DNA methylation analysis technology.Methionine Deprivation Induces a Targetable Vulnerability in Triple-Negative Breast Cancer Cells by Enhancing TRAIL Receptor-2 ExpressionBID mediates selective killing of APC-deficient cells in intestinal tumor suppression by nonsteroidal antiinflammatory drugs.Exploiting the mitochondrial unfolded protein response for cancer therapy in mice and human cellsIn Vitro Morphological Assessment of Apoptosis Induced by Antiproliferative Constituents from the Rhizomes of Curcuma zedoaria.Gene regulatory and clinical effects of interferon β in patients with metastatic melanoma: a phase II trial
P2860
Q23913664-0E35091F-6574-47E7-AA78-8BA556CEA6B4Q24302531-EB101EE4-C01D-44FF-BBC9-C5C813FAF174Q24599662-5A524523-6CE4-4C03-B7F1-0909D7B53358Q26749610-AD589436-B562-4A9C-96FD-FE7377D5FA55Q26766570-5D39C873-A80A-4375-8DD9-989BDC54EB17Q26768267-C3F6A5B9-01AD-42DC-B70F-41675D88481BQ27024422-5D946306-80EB-440F-B2FB-854B3C3D1BD2Q27853200-97660F30-F824-42D2-8380-858CB53C2AD6Q28084613-966838CA-F4FB-40BE-9709-B9F03646EA25Q28115758-60D9AFCF-1BF8-421B-A135-921048989AB4Q28474952-665E6971-D6A5-490A-99B4-D835FBDB6723Q28729017-768C69CC-2F53-42F7-9F8B-6ED62EFEAFC8Q28831051-682F90F3-5A49-4B81-9484-ADB9F4C879FCQ29994621-D5E98546-C722-40F5-9877-D1E5D66EC078Q30479062-0CF6D847-F121-4F25-A676-552C7A89E157Q33566824-CBFEA33D-D0A0-48ED-BB06-BFE6F3FE4EE9Q33569854-ED25B64A-993E-4609-B225-F27C62D55D61Q33578562-E71E20E3-3A11-49EB-B507-9E03A87BF0EDQ33636849-B29D27A8-AB4B-415D-B9ED-98F72C9EBD25Q33658593-12889695-C943-4EA4-B2D6-198CF8D272F2Q33739941-7CDED647-A157-4EDF-B835-0AF05CB5C394Q33755766-6AEEC68F-4C79-489F-B9C4-D10399F488F2Q33768428-AFAABCBC-3F83-452E-92FF-A5FF3C4ECAE6Q33802751-1DA5788F-39D6-4CFC-8A84-512D464163A4Q33842416-1A8FBB11-11A9-42FB-923B-744BD18C3215Q33903806-C739475B-C1B9-4A40-84CF-A15056DF620BQ33985939-50DBFCDF-1540-4C91-B777-7E32BDE91356Q34060387-C4F57D23-1E92-42FC-8577-36E94B2C7EC1Q34076762-CA3CB2CF-74C0-4B7A-9E7B-8ECA9D166F7BQ34219368-0279A8B4-7472-486C-8AF7-23F7CE308EC0Q34227759-19FFD0D7-B2A5-4A63-B4A4-C44AC993F218Q34241371-5E3B835E-5011-4FF3-A839-185FF73CD1EBQ34286028-A2DA6BA3-F4B6-4E97-89AB-F722ABE52AA6Q34344093-8E4938C3-F378-4F4B-AA84-2C1D58BC9D6EQ34419090-3224D09D-9C53-4EC3-8D50-243D3F2C6B9BQ34464915-F355E5FA-666F-4F72-A9CF-8AD0CDA48DEFQ34581082-317BF34B-26B0-4F29-990E-78449266D4A2Q34755334-C62078A7-BA06-47BC-9ECC-7421D8E512F8Q34769293-A08FD940-7F72-4649-8EDC-F91F440BC3A0Q34875311-48175062-5A07-4DFC-B403-D5F1FECB87E9
P2860
Directing cancer cells to self-destruct with pro-apoptotic receptor agonists.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Directing cancer cells to self-destruct with pro-apoptotic receptor agonists.
@en
Directing cancer cells to self-destruct with pro-apoptotic receptor agonists.
@nl
type
label
Directing cancer cells to self-destruct with pro-apoptotic receptor agonists.
@en
Directing cancer cells to self-destruct with pro-apoptotic receptor agonists.
@nl
prefLabel
Directing cancer cells to self-destruct with pro-apoptotic receptor agonists.
@en
Directing cancer cells to self-destruct with pro-apoptotic receptor agonists.
@nl
P356
P1476
Directing cancer cells to self-destruct with pro-apoptotic receptor agonists.
@en
P2093
Avi Ashkenazi
P2888
P304
P356
10.1038/NRD2637
P577
2008-11-07T00:00:00Z